GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of survodutide vs glucagon — genuinely asking which matters more — 58 comments in the full submission. View in context.
853
c/survodutide·submitted 8 months ago by u/patient_labslip_log

survodutide vs glucagon — genuinely asking which matters more

Questionbranch of 13 comments

Confession thread, sort of. I went from 15mg to 7.5mg much faster than I should have because the scale had stalled and I got impatient. The stall broke about 13 weeks later, at which point I had no way of knowing whether the dose increase did anything or whether it would have broken anyway. So now I have early…

Read the full submission and all 58 comments →

This branch

13 comments, started 8 months ago
u/customs_seizure_sid30 points·8 months ago

Yeah, glucagon co-agonism is genuinely different.

replysharereportpermalink
u/patient_labslip_log20 points·8 months ago

This is correct. Do not generalise from tirzepatide.

replysharereportpermalink
u/draw_up_dizzy28 points·8 months ago

do not generalise from tirzepatide

replysharereportpermalink
u/refund_ledger9 points·8 months ago

the MASH indication changes the risk calculus

replysharereportpermalink
u/whois_wanda22 points·8 months ago·edited

You have restated the marketing copy. What is the actual substance here.

replysharereportpermalink
u/lina_ndiaye6 points·8 months ago

the safety profile is not just tirzepatide amplified

replysharereportpermalink
u/kaia_kuusela7 points·8 months ago·edited

The early fullness was genuinely awful for three weeks and then simply stopped. I know that is not useful information, but it is what happened.

replysharereportpermalink
u/peak_area_peteanalytical3 points·8 months ago

do not generalise from tirzepatide

replysharereportpermalink
u/peak_area_peteanalytical1 point·8 months ago

Strongly agree. The safety story is separate.

replysharereportpermalink
u/crosspost_bot_no20 points·8 months ago

Yeah, glucagon co-agonism is genuinely different.

Yes, exactly this, and it is the bit that took me 77 weeks to accept.

replysharereportpermalink
u/patient_labslip_logOP13 points·8 months ago

Small correction: the trial was 23 weeks, not 25. Does not change your point but people will quote it.

replysharereportpermalink
u/camila_trevino4 points·8 months ago·edited

Which trial arm?

replysharereportpermalink
u/valeria_karlsen9 points·8 months ago·edited

hepatic fat and survodutide are the story

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.